Comparative Pharmacology
Head-to-head clinical analysis: AQUASOL A versus VI DOM A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUASOL A versus VI DOM A.
AQUASOL A vs VI-DOM-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin A is essential for vision, epithelial differentiation, bone growth, reproduction, and immune function. It acts as a retinol-binding protein that regulates gene expression through retinoic acid receptors.
Retinol binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell growth, differentiation, and immune function.
100,000 to 200,000 IU intramuscularly once monthly for prophylaxis; 50,000 to 100,000 IU intramuscularly daily for 3 days for severe deficiency.
1 mL intramuscular injection once weekly; each mL contains 100,000 IU vitamin A (as retinyl palmitate) and 50,000 IU vitamin D (as ergocalciferol).
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (mean 36 h); prolonged in renal impairment; clinical context: steady-state achieved in ~5-7 days with daily dosing.
The terminal elimination half-life of vitamin A is 10-12 hours for retinol, but due to hepatic storage and enterohepatic recirculation, the overall body half-life can extend to 2-3 weeks with chronic dosing.
Renal: ~60% as metabolites; fecal: ~30% as unchanged drug and metabolites; biliary: ~10%.
Vitamin A is primarily excreted via bile and feces as metabolites. Renal excretion accounts for less than 5% of an oral dose. Unchanged vitamin A is not significantly excreted in urine.
Category C
Category C
Vitamin A
Vitamin A